One Australian dies every six hours due to skin cancer,1 underpinning the need for further treatment options for patients with melanoma.

Recent PBS listings have increased the treatments available for healthcare professionals, offering expanded access to treatment options, including dual I-O, to a broad range of patients.2

Learn more about these changes and what this means for your practice:

Learn from leading Australian
experts as they discuss
dual I-O and implications for practice

Hear their opinions  

Do you have patients currently
treated with I-O in need of
educational resources and support?

Find out more  

Understand how this affects
PBS treatment sequencing
in melanoma

Access the PBS sequence tool  

Are you up to date with the
latest clinical data for dual I-O
in metastatic melanoma?

View resources  

This website is for Australian healthcare professionals only. If you are a patient or a member of the general public looking for information on
immuno-oncology, please visit the my-IO patient website.

I-O = immuno-oncology; PBS = Pharmaceutical Benefits Scheme.

References: 1.Melanoma Institute Australia. Melanoma Facts. Available at: https://melanoma.org.au/about-melanoma/melanoma-facts/. Accessed May 2024. 2.Pharmaceutical Benefits Scheme. www.pbs.gov.au.

© 2024 Bristol-Myers Squibb.
BMS Medical Information: 1800 067 567. Bristol-Myers Squibb Australia Pty Ltd, ABN 33 004 333 322,
4 Nexus Court, Mulgrave, VIC 3160. ONC-AU-2400104. May 2024. BRMSOY0177.